参考文献/References:
[1] Du X,Guo L,Xia S,et al. Atrial fibrillation prevalence,awareness and management in a nationwide survey of adults in China[J]. Heart,2021,107(7):535-541.
[2] Reddy VY,Doshi SK,Kar S,et al. 5-year outcomes after left atrial appendage closure:from the PREVAIL and PROTECT AF trials[J]. J Am Coll Cardiol,2017,70(24):2964-2975.
[3] Holmes DR,Reddy VY,Turi ZG,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:a randomised non-inferiority trial[J]. Lancet,2009,374(9689):534-542.
[4] Holmes DR Jr,Kar S,Price MJ,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy:the PREVAIL trial[J]. J Am Coll Cardiol,2014,64(1):1-12.
[5] Dukkipati SR,Kar S,Holmes DR,et al. Device-related thrombus after left atrial appendage closure:incidence,predictors,and outcomes[J]. Circulation,2018,138(9):874-885.
[6] Reddy VY,M?bius-Winkler S,Miller MA,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation:the ASAP study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J]. J Am Coll Cardiol,2013,61(25):2551-2556.
[7] Boersma LV,Ince H,Kische S,et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation:1-year follow-up outcome data of the EWOLUTION trial[J]. Heart Rhythm,2017,14(9):1302-1308.
[8] Boersma LV,Ince H,Kische S,et al. Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology:final 2-year outcome data of the EWOLUTION trial focusing on history of stroke and hemorrhage[J]. Circ Arrhythm Electrophysiol,2019,12(4):e006841.
[9] Fauchier L,Cinaud A,Brigadeau F,et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for?atrial?fibrillation[J]. J Am Coll Cardiol,2018,71(14):1528-1536.
[10] Kar S,Doshi SK,Sadhu A,et al. Primary outcome evaluation of a next-generation left atrial appendage closure device:results from the PINNACLE FLX trial[J]. Circulation,2021,143(18):1754-1762.
[11] Hildick-Smith D,Landmesser U,Camm AJ,et al. Left atrial appendage occlusion with the Amplatzer? Amulet? device:full results of the prospective global observational study[J]. Eur Heart J,2020,41(30):2894-2901.
[12] Ali M,Rigopoulos AG,Mammadov M,et al. Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation[J]. BMC Cardiovasc Disord,2020,20(1):78.
[13] Simard T,Jung RG,Lehenbauer K,et al. Predictors of device-related thrombus following percutaneous left atrial appendage?occlusion[J]. J Am Coll Cardiol,2021,78(4):297-313.
[14] Iriart X,Metras A,Coiffic A,et al. Late device-related thrombus after left atrial appendage closure:never let your guard down[J]. Eur Heart J,2021,42(10):1050.
[15] Sedaghat A,Nickenig G,Schrickel JW,et al. Incidence,predictors and outcomes of device-related thrombus after left atrial appendage closure with the WATCHMAN device-Insights from the EWOLUTION real world registry[J]. Catheter Cardiovasc Interv,2021,97(7):E1019-E1024.
[16] Saw J,Tzikas A,Shakir S,et al. Incidence and clinical impact of device-associated thrombus and?peri-device leak following left atrial appendage closure with the?Amplatzer cardiac plug[J]. JACC Cardiovasc Interv,2017,10(4):391-399.
[17] Alkhouli M,Busu T,Shah K,et al. Incidence and clinical impact of?device-related thrombus following?percutaneous left?atrial?appendage occlusion:a meta-analysis[J]. JACC Clin Electrophysiol,2018,4(12):1629-1637.
[18] Sedaghat A,Vij V,Al-Kassou B,et al. Device-related thrombus after left atrial appendage closure:data on thrombus characteristics,treatment strategies,and clinical outcomes from the EUROC-DRT-Registry[J]. Circ Cardiovasc Interv,2021,14(5):e010195.
[19] Rashid HN,Layland J. Association between device-related thrombus and the neo-appendage with left-atrial appendage occlusion devices[J]. Eur Heart J,2021,42(10):1047-1048.
[20] Lakkireddy D,Thaler D,Ellis CR,et al. Amplatzer amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis(Amulet IDE):a randomized, controlled trial[J]. Circulation,2021,144(19):1543-1552.
[21] Pracon R,Bangalore S,Dzielinska Z,et al. Device thrombosis after percutaneous left atrial appendage occlusion is related to patient and procedural characteristics but not to duration of postimplantation dual antiplatelet therapy[J]. Circ Cardiovasc Interv,2018,11(3):e005997.
[22] Freixa X,Cepas-Guillen P,Flores-Umanzor E,et al. Pulmonary ridge coverage and device-related thrombosis after left atrial appendage occlusion[J]. EuroIntervention,2021,16(15):e1288-e1294.
[23] Fender EA,El Sabbagh A,Al-Hijji M,et al. Left atrial appendage peridevice leak presenting with stroke[J]. JACC Cardiovasc Interv,2019,12(14):e123-e125.
[24] Bai Y,Xue X,Duenninger E,et al. Real-world survival data of device-related thrombus following left atrial appendage closure:4-year experience from a single center[J]. Heart Vessels,2019,34(8):1360-1369.
[25] Sommer RJ,Lamport R,Melanson D,et al. Preclinical assessment of a novel conformable foam-based left atrial appendage closure device[J]. Biomed Res Int,2021,2021:4556400.
[26] Sommer RJ, Kim JH, Szerlip M,et al. Conformal left atrial appendage seal device for left atrial appendage closure:first clinical use[J]. JACC Cardiovasc Interv,2021,14(21):2368-2374.
[27] S?ndergaard L,Wong YH,Reddy VY,et al. Propensity-matched comparison of oral?anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN[J]. JACC Cardiovasc Interv,2019,12(11):1055-1063.
[28] Osman M,Busu T,Osman K,et al. Short-term antiplatelet versus anticoagulant therapy after left atrial appendage occlusion:a systematic review and meta-analysis[J]. JACC Clin Electrophysiol,2020,6(5):494-506.
[29] Della Rocca DG,Magnocavallo M,di Biase L,et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion[J]. JACC Cardiovasc Interv,2021,14(21):2353-2364.
[30] Bergmann MW,Ince H,Kische S,et al. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy:results of the DAPT subgroup from the EWOLUTION all-comers study[J]. EuroIntervention,2018,13(17):2003-2011.
[31] Weise FK,Bordignon S,Perrotta L,et al. Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices[J]. EuroIntervention,2018,13(18):e2138-e2146.
[32] Rodriguez-Gabella T,Nombela-Franco L,Regueiro A,et al. Single antiplatelet therapy following left atrial appendage closure in patients with contraindication to anticoagulation[J]. J Am Coll Cardiol,2016,68(17):1920-1921.
[33] Korsholm K,Nielsen KM,Jensen JM,et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy[J]. EuroIntervention,2017,12(17):2075-2082.
[34] Lempereur M,Aminian A,Freixa X,et al. Device-associated thrombus formation after left atrial appendage occlusion:a systematic review of events reported with the Watchman,the Amplatzer Cardiac Plug and the Amulet[J]. Catheter Cardiovasc Interv,2017,90(5):E111-E121.
[35] Salaun E,Deharo JC,Habib G,et al. Extensive endothelialization or thrombus?related to new-generation left?atrial appendage occluders[J]. JACC Clin Electrophysiol,2017,3(7):787-788.
[36] Ciconte G,Conti M,Baldi M,et al. Thrombosis on a left atrial appendage occluder device:the double-edged sword of stroke prevention strategies in atrial fibrillation[J]. J Cardiovasc Med(Hagerstown),2017,18(11):920-921.
[37] Li X,Zhang X,Jin Q,et al. The impact of dabigatran and rivaroxaban on variation of platelet activation biomarkers and DRT following percutaneous left atrial appendage closure[J]. Front Pharmacol,2021,12:723905.
相似文献/References:
[1]安硕研,郑金刚.左心耳封堵术预防心源性卒中的进展[J].心血管病学进展,2019,(6):869.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.008]
AN Shuoyan,ZHENG Jingang.Left Atrial Appendage Closure for Prevention of Cardiogenic Stroke[J].Advances in Cardiovascular Diseases,2019,(5):869.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.008]
[2]彭金华,王平,胡婧,等.左心耳封堵术对非瓣膜性心房颤动患者心脏利尿钠肽分泌功能的影响[J].心血管病学进展,2019,(6):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
PENG Jinhua,WANG PingHU Jing,YANG Jingqi,et al.Effect of Left Atrial Appendage Closure on Cardiac Natriuretic Peptide Secretion in Patients with Nonvalvular Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(5):873.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.009]
[3]朱世杰,郑慕晗,张建武,等.心脏CT在左心耳封堵术中的应用价值[J].心血管病学进展,2020,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.004]
ZHU Shijie,ZHENG Muhan,ZHANG Jianwu,et al.Application of Cardiac CT in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2020,(5):11.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.004]
[4]金铁托 阮中宝.左心耳封堵术对患者系统内稳态的影响[J].心血管病学进展,2020,(12):1268.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.011]
JIN Tietuo,RUAN Zhongbao.Effect of Left Atrial Appendage Closure on Systemic Homeostasis in Patients[J].Advances in Cardiovascular Diseases,2020,(5):1268.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.011]
[5]李亚会 黄从新.左心耳封堵术常见并发症及其防治[J].心血管病学进展,2021,(5):408.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.006]
LI YahuiHUANG Congxin.Common Complications of Left Atrial Appendage Occlusion and Its Prevention and Treatment[J].Advances in Cardiovascular Diseases,2021,(5):408.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.006]
[6]吴阳 杨桂荣 张波 陈各才.双源CT在左心耳封堵术前评估及指导选择WatchmanTM封堵器型号的应用[J].心血管病学进展,2021,(4):374.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.020]
WU Yang,YANG Guirong,ZHANG Bo,et al.The Application of Dual Source CT in Preoperative Evaluation of Left Atrial Appendage Occlusion and Size Selection of Watchman TM Occluder.com[J].Advances in Cardiovascular Diseases,2021,(5):374.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.020]
[7]王璐 李耀东.TAVR合并心房颤动抗凝策略的研究进展[J].心血管病学进展,2022,(8):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
WANG Lu,LI Yaodong.Anticoagulation Strategy in Patients After TAVR Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(5):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
[8]魏志梁 孙雨可 尹月娇 孙守刚.心房颤动合并慢性肾脏病患者的左心耳封堵治疗研究进展[J].心血管病学进展,2022,(9):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
WEI Zhiliang,SUN Yuke,YIN Yuejiao,et al.Left Atrial Appendage Closure in Patients with Atrial Fibrillation Complicated with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2022,(5):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
[9]邓蕊 李洪仕 蔡衡.左心耳封堵术对非瓣膜性心房颤动合并冠状动脉性心脏病的价值[J].心血管病学进展,2022,(11):966.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.002]
DENG Rui,LI Hongshi,CAI Heng.Value of Left Atrial Appendage Closure on Non-Valvular Atrial Fibrillation with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2022,(5):966.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.002]
[10]加依娜·加尔肯 汤宝鹏 周贤惠 李耀东 芦颜美.非瓣膜性心房颤动患者“一站式”手术策略的有效性和安全性:单中心经验[J].心血管病学进展,2022,(12):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
Jiayina Jiaerken,TANG Baopeng,ZHOU Xianhui,et al.Effectiveness and Safety of "One-Step" Procedure in Patients with Non-Valvular Atrial Fibrillation:A Single Center Experience?/html>[J].Advances in Cardiovascular Diseases,2022,(5):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]